Physician profile
Michael R Tekulve
NPI 1760601025
$1,792.76
in general payments reported to CMS, 2019-2025
21 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $321 · 2023: $417 · 2024: $370 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $619.07 | 2019-2025 | Phasix Mesh |
| Organogenesis INC. | $213.01 | 2023-2025 | Puraply Wound Matrix, Puraply, Apligraf |
| Smith+Nephew, INC. | $140.04 | 2023-2025 | Collagenase Santyl, Iodosorb Ointment 40g USA |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2019 | |
| Kerecis Limited | $92.75 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Paratek Pharmaceuticals, INC. | $91.92 | 2023-2025 | Nuzyra |
| W. L. Gore & Associates, INC. | $84.59 | 2023 | Gore Synecor Biomaterial |
| Innovation Technologies INC | $60.86 | 2024-2025 | Irrisept |
| Lexicon Pharmaceuticals, INC. | $57.68 | 2024 | |
| Madrigal Pharmaceuticals | $55.97 | 2025 | Rezdiffra |
| Lilly USA, LLC | $44.15 | 2024-2025 | Omvoh |
| My01 INC. | $40.06 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Biotissue Holdings INC. | $35.48 | 2024-2025 | |
| Mimedx Group, INC. | $33.31 | 2024 | |
| Polymedics Innovations INC. | $19.82 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.71 | 2024 | Voquezna |
| Solventum Corporation | $18.13 | 2025 | Activ.A.C. |
| Genzyme Corporation | $17.78 | 2024 | |
| Aimmune Therapeutics, INC. | $15.05 | 2024 | |
| Sebela Pharmaceuticals INC. | $12.82 | 2023 | Suflave |
| Reprise Biomedical, INC. | $11.07 | 2025 | Miro 3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tekulve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.